A Parallel Group, Randomized, Open-label Study to Investigate the Effect of the Intravaginally Administered Antimycotic Miconazole, Antibiotic Clindamycin, Spermicide Nonoxynol-9, or Co-usage of Tampons on 3 Consecutive Days on the Pharmacokinetics of Anastrozole and Levonorgestrel Released From an Intra-vaginal Ring in Healthy Young Women

To investigate the pharmacokinetic effect of a vaginally administered antimycotic (miconazole), antibiotic (clindamycin), spermicide (nonoxynol-9) or the concomitant use of tampons during the use of an intravaginal ring releasing anastrozole and levonorgestrel

开始日期2015-09-15

申办/合作机构

Bayer AG

NCT01593124 / Completed临床2期IIT

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

This study investigates the response of vaginal and cervical tissue after exposure to three vaginal products: hydroxyethyl cellulose (HEC) placebo, nonoxynol-9 (N9) and imiquimod (IMQ) cream.

开始日期2012-05-01

申办/合作机构

Contraception Research and Development

NCT00000926 / Completed临床3期IIT

Phase III Nonoxynol-9 and HIV Infection

The purpose of this study is to see if nonoxynol-9 (N-9) gel used in the vagina can prevent the spread of HIV.
Most of the people with HIV in the world today live in southern Africa. Because this population is not likely to use condoms, an HIV-prevention method that women can control is needed. N-9 used in the vagina may help prevent the spread of HIV and other sexually transmitted diseases.

开始日期-

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与壬苯醇醚-9 相关的临床结果

登录后查看更多信息

100 项与壬苯醇醚-9 相关的转化医学

登录后查看更多信息

100 项与壬苯醇醚-9 相关的专利（医药）

登录后查看更多信息

605

项与壬苯醇醚-9 相关的文献（医药）

2024-07-22·BIOTECHNIQUES

Transitioning from Triton X-100 to Tergitol 15-S-9: impacts on diagnostic assays using viral PCR sample solution

Article

作者: Zorzoli, Azul ; Sakka, Noha El ; Gunson, Rory ; Bennet-Slater, Susan ; Tait-Burkard, Christine ; Nicholson, Scott ; Daniels, Alison ; MacLean, Alasdair ; Hughes, Stephen ; Templeton, Kate

In 2019, the European Union banned Triton X-100, a detergent widely used in laboratory diagnostics, including the Viral PCR Sample Solution (VPSS), and urged manufacturers to find environmentally sustainable alternatives. Tergitol 15-S-9 (VPSS2) has been proposed as an alternative surfactant. This multicenter study evaluated the effectiveness of VPSS2, a Tergitol-based viral solution, as a replacement for VPSS. Our results show the equivalent performance of VPSS2 to VPSS for nucleic acid extraction and viral stability over time at different temperatures. The new VPSS formulation was also tested against external quality assurance panels and clinical samples. The results of this work support adopting this modified viral PCR sample solution to replace Triton X-100-containing viral transport solutions.

2024-01-01·Food chemistry

Cloud point extraction of carbendazim fungicide from strawberry samples and amperometric detection with boron doped diamond

Article

作者: Caixeta-Neta, Antonia ; Ribeiro, Gabriela C ; Andrade, Leonardo S ; de Amorim, Kamila P

The cloud point extraction (Tergitol® surfactant) method was used for the first time to extract and preconcentrate the fungicide carbendazim (CBZ) from strawberry samples, while electrochemical detection (boron doped diamond electrode) in association with high performance liquid chromatography (HPLC-EC) was used for the determination of CBZ. The variables of bath temperature, ultrasonic stirring time, mass of NaCl and amount of surfactant were investigated using a 2⁴ full factorial design. Limits of detection (LOD, S/N = 3) and quantification (LOQ) of 3.42 × 10^-8 mol/L (or 6.54 µg/L) and 6.84 × 10^-8 mol/L (or 13.1 µg/L), respectively, were obtained for the CPE processes, considering the value of the preconcentration factor obtained (9.12). The method was validated based on linearity, intra-day and inter-day recovery tests, accuracy and precision. The proposed method was applied to strawberry samples from local commercial establishments and different procedures for washing and sanitizing strawberry fruits were also evaluated.

2023-06-30·Molecular human reproduction

Safety of multiple administrations of spermicidal LL-37 antimicrobial peptide into the mouse female reproductive tract.

Article

作者: Burke Schinkel, Stephanie C ; Angel, Jonathan ; Tanphaichitr, Nongnuj ; Lee, Seung Gee ; Kiattiburut, Wongsakorn

We have previously demonstrated spermicidal activity of LL-37 antimicrobial peptide on mouse/human sperm and its contraceptive effects in female mice. With its microbicidal action against Neisseria gonorrhoeae, LL-37 warrants development into a multipurpose prevention technology (MPT) agent for administering into the female reproductive tract (FRT). However, it is important to verify that multiple administrations of LL-37 do not lead to damage of FRT tissues and/or irreversible loss of fecundity. Herein, we transcervically injected LL-37 (36 µM-10× spermicidal dose) into female mice in estrus in three consecutive estrous cycles. A set of mice were sacrificed for histological assessment of the vagina/cervix/uterus 24 h after the last injection, while the second set were artificially inseminated with sperm from fertile males 1 week afterwards, and then monitored for pregnancy. Mice injected with PBS in parallel were regarded as negative controls, whereas those injected with vaginal contraceptive foam (VCF, available over the counter), containing 12.5% nonoxynol-9, served as positive controls for vaginal epithelium disruption. We demonstrated that the vagina/cervix/uterus remained normal in both LL-37-injected and PBS-injected mice, which also showed 100% resumption of fecundity. In contrast, VCF-injected mice showed histological abnormalities in the vagina/cervix/uterus and only 50% of them resumed fecundity. Similarly, LL-37 multiply administered intravaginally caused no damage to FRT tissues. While our results indicate the safety of multiple treatments of LL-37 in the mouse model, similar studies have to be conducted in non-human primates and then humans. Regardless, our study provides an experimental model for studying in vivo safety of other vaginal MPT/spermicide candidates.

项与壬苯醇醚-9 相关的新闻（医药）

2023-08-11

·PRNewswire

Medical Polyoxymethylene (POM) Market to grow by USD 2,719.15 million from 2022 to 2027; Rising demand from drug contact and delivery applications boosts the market - Technavio

NEW YORK, Aug. 10, 2023 /PRNewswire/ -- The medical polyoxymethylene (POM) market is set to grow by USD 2,719.15 million from 2022 to 2027. However, the growth momentum will progress at a CAGR of 5.4% during the forecast period, according to Technavio. The medical polyoxymethylene (pom) market is fragmented, and the companies are seeking strong partnerships with automotive, industrial, and commercial companies to compete in the market. ADDTEK Chemical, Asahi Kasei Corp., Ascend Performance Materials Operations LLC, Avient Corp., BASF SE, Celanese Corp., Daicel Corp., DuPont de Nemours Inc., Ensinger GmbH, Inventro Polymers, Kolon Plastics Inc., LG Chem Ltd., Mitsubishi Chemical Corp., Saudi Basic Industries Corp., Westlake Plastics, Yuntianhua Group Co. Ltd., and Korea Engineering Plastics Co. Ltd. are some of the major market participants -. To know about the company's offerings - Request a sample report Continue Reading Technavio has announced its latest market research report titled Global Medical Polyoxymethylene (POM) Market Medical Polyoxymethylene (POM) Market 2023-2027: Scope Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The medical polyoxymethylene (pom) market report covers the following areas: Medical Polyoxymethylene (POM) Market Size Medical Polyoxymethylene (POM) Market Trends Medical Polyoxymethylene (POM) Market Industry Analysis Porter's Five Forces Analysis Customer Landscape The medical polyoxymethylene (POM) market is fragmented, and the degree of fragmentation will accelerate. The rising demand from drug contact and delivery applications will offer immense growth opportunities. However, the stringent regulations on polyoxymethylene will hamper the market growth. Medical Polyoxymethylene (POM) Market 2023-2027: Drivers & Challenges DRIVERS The increasing demand from drug contact and delivery applications drives the medical polyoxymethylene (POM) market growth. One of the main applications of polyoxyethylene is in the manufacturing of medical devices that require constant cleaning and sterilization. There is increasing adoption of polyoxyethylene due to its several properties such as high strength and stiffness and low-frictional properties. Additionally, it is extensively used in the manufacture of implantable medical devices, which needs materials that are biocompatible. Furthermore, there is an increasing preference for polyoxyethylene for orthopedic implants and dental implants due to its biocompatible and lightweight properties. Hence, such factors are expected to drive market growth during the forecast period. TRENDS The emerging applications in tissue engineering are a primary trend in the market during the forecast period. One of the main applications of polyoxyethylene includes engineering thermoplastics mainly due to its mechanical properties, high stiffness, low friction coefficient, and dimensional stability. The main emerging trend in the market is the use of polyoxymethylene in tissue engineering. There is increasing demand for scaffold materials over the past decade as they offer a platform for tissue repair and regeneration. Some of the main advantages of polyoxymethylene-based scaffold materials are its high level of biocompatibility as well as high mechanical strength that can withstand the mechanical stresses and strains that arise during surgical implantation and in-vivo tissue growth. Hence, such factors are expected to drive market growth during the forecast period. CHALLENGES Stringent regulations on polyoxyethylene are a major challenge hindering the medical polyoxymethylene market growth. There is an increase in the adoption of polyoxyethylene across the hospital sector due to its various applications. Some of the key medical devices which are manufactured using polyoxyethylene include valves, cannulas, connectors, and other small devices. However, there are severe side effects and reactions in patients due to the presence of polyoxyethylene. Some of the key allergic reactions which are caused due to polyoxyethylene include mild skin irritation or severe anaphylaxis. Hence, such factors can negatively impact market growth which in turn can hinder the medical polyoxymethylene market growth during the forecast period. To learn more about the global trends impacting the future of market research, download a PDF sample Medical Polyoxymethylene (POM) Market 2023-2027: Segment Analysis Type Homopolymer POM Copolymer POM Application Dialysis Machine Handles For Surgical Instruments Inhalers Others Geography APAC North America Europe South America Middle East And Africa Medical Polyoxymethylene (POM) Market 2023-2027: Segmentation Highlights The market share growth by the homopolymer POM segment will be significant during the forecast period. There is increasing adoption of the homopolymer POM segment across healthcare sectors due to its several properties such as high strength, rigidity, and chemical resistance. Additionally, there is a growing popularity for homopolymer POM for several medical applications, including stethoscopes and spare parts, sphygmomanometers and spares, otoscopes, ophthalmoscopes, pulse oximeters, fetal doppler, and others. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period. The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies, growth strategies, product innovations, new product launches, investments, and growth in market share, among others Buy the Report Medical Polyoxymethylene (POM) Market 2023-2027: Key Highlights CAGR of the market during the forecast period 2023-2027 Detailed information on factors that will assist Medical Polyoxymethylene (POM) Market growth during the next five years Estimation of the Medical Polyoxymethylene (POM) Market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the Medical Polyoxymethylene (POM) Market across APAC, North America, Europe, South America, and the Middle East and Africa Analysis of the market's competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of Medical Polyoxymethylene (POM) Market players Get Instant access to 17000+ market research report Technavio's Subscription Platform Related Reports: The squalene market is estimated to grow by USD 64.75 million between 2022 and 2027 exhibiting a CAGR of 7.36%. Squalene is a natural 30-carbon triterpene. It is an oily liquid hydrocarbon found in plants and animals. Squalene is largely found in shark liver oil as it contributes approximately one-third of the body weight of the fish. In recent years, squalene has also been derived from renewable plant sources such as rice bran oil, olive oil, wheat germ, and amaranth oil. The hot melt adhesives market size is estimated to grow at a CAGR of 7.28% between 2022 and 2027. The market size is forecast to increase by USD 4,396.66 million. This hot melt adhesives market report extensively covers market segmentation by product (ethylene-vinyl acetate (EVA), rubber, polyolefin, polyurethane, and others), application (packaging, nonwoven hygiene products, furniture, and woodworking, automobile, and footwear, and others), and geography (APAC, North America, Europe, South America, and the Middle East and Africa). High application in sanitary materials is one of the key factors driving the growth of the global hot melt adhesives market. Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Market Segmentation by Application Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global medical polyoxymethylene (POM) market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on global medical polyoxymethylene (pom) market 2017 - 2021 ($ million) 4.2 Type Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million) 4.3 Application Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Type 6.1 Market segments Exhibit 30: Chart on Type - Market share 2022-2027 (%) Exhibit 31: Data Table on Type - Market share 2022-2027 (%) 6.2 Comparison by Type Exhibit 32: Chart on Comparison by Type Exhibit 33: Data Table on Comparison by Type 6.3 Homopolymer POM - Market size and forecast 2022-2027 Exhibit 34: Chart on Homopolymer POM - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Homopolymer POM - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Homopolymer POM - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Homopolymer POM - Year-over-year growth 2022-2027 (%) 6.4 Copolymer POM - Market size and forecast 2022-2027 Exhibit 38: Chart on Copolymer POM - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Copolymer POM - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Copolymer POM - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Copolymer POM - Year-over-year growth 2022-2027 (%) 6.5 Market opportunity by Type Exhibit 42: Market opportunity by Type ($ million) Exhibit 43: Data Table on Market opportunity by Type ($ million) 7 Market Segmentation by Application 7.1 Market segments Exhibit 44: Chart on Application - Market share 2022-2027 (%) Exhibit 45: Data Table on Application - Market share 2022-2027 (%) 7.2 Comparison by Application Exhibit 46: Chart on Comparison by Application Exhibit 47: Data Table on Comparison by Application 7.3 Dialysis machine - Market size and forecast 2022-2027 Exhibit 48: Chart on Dialysis machine - Market size and forecast 2022-2027 ($ million) Exhibit 49: Data Table on Dialysis machine - Market size and forecast 2022-2027 ($ million) Exhibit 50: Chart on Dialysis machine - Year-over-year growth 2022-2027 (%) Exhibit 51: Data Table on Dialysis machine - Year-over-year growth 2022-2027 (%) 7.4 Handles for surgical instruments - Market size and forecast 2022-2027 Exhibit 52: Chart on Handles for surgical instruments - Market size and forecast 2022-2027 ($ million) Exhibit 53: Data Table on Handles for surgical instruments - Market size and forecast 2022-2027 ($ million) Exhibit 54: Chart on Handles for surgical instruments - Year-over-year growth 2022-2027 (%) Exhibit 55: Data Table on Handles for surgical instruments - Year-over-year growth 2022-2027 (%) 7.5 Inhalers - Market size and forecast 2022-2027 Exhibit 56: Chart on Inhalers - Market size and forecast 2022-2027 ($ million) Exhibit 57: Data Table on Inhalers - Market size and forecast 2022-2027 ($ million) Exhibit 58: Chart on Inhalers - Year-over-year growth 2022-2027 (%) Exhibit 59: Data Table on Inhalers - Year-over-year growth 2022-2027 (%) 7.6 Others - Market size and forecast 2022-2027 Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.7 Market opportunity by Application Exhibit 64: Market opportunity by Application ($ million) Exhibit 65: Data Table on Market opportunity by Application ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 67: Chart on Market share by geography 2022-2027 (%) Exhibit 68: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 69: Chart on Geographic comparison Exhibit 70: Data Table on Geographic comparison 9.3 APAC - Market size and forecast 2022-2027 Exhibit 71: Chart on APAC - Market size and forecast 2022-2027 ($ million) Exhibit 72: Data Table on APAC - Market size and forecast 2022-2027 ($ million) Exhibit 73: Chart on APAC - Year-over-year growth 2022-2027 (%) Exhibit 74: Data Table on APAC - Year-over-year growth 2022-2027 (%) 9.4 North America - Market size and forecast 2022-2027 Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.5 Europe - Market size and forecast 2022-2027 Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.6 South America - Market size and forecast 2022-2027 Exhibit 83: Chart on South America - Market size and forecast 2022-2027 ($ million) Exhibit 84: Data Table on South America - Market size and forecast 2022-2027 ($ million) Exhibit 85: Chart on South America - Year-over-year growth 2022-2027 (%) Exhibit 86: Data Table on South America - Year-over-year growth 2022-2027 (%) 9.7 Middle East and Africa - Market size and forecast 2022-2027 Exhibit 87: Chart on Middle East and Africa - Market size and forecast 2022-2027 ($ million) Exhibit 88: Data Table on Middle East and Africa - Market size and forecast 2022-2027 ($ million) Exhibit 89: Chart on Middle East and Africa - Year-over-year growth 2022-2027 (%) Exhibit 90: Data Table on Middle East and Africa - Year-over-year growth 2022-2027 (%) 9.8 US - Market size and forecast 2022-2027 Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%) 9.9 China - Market size and forecast 2022-2027 Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%) 9.10 Germany - Market size and forecast 2022-2027 Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.11 India - Market size and forecast 2022-2027 Exhibit 103: Chart on India - Market size and forecast 2022-2027 ($ million) Exhibit 104: Data Table on India - Market size and forecast 2022-2027 ($ million) Exhibit 105: Chart on India - Year-over-year growth 2022-2027 (%) Exhibit 106: Data Table on India - Year-over-year growth 2022-2027 (%) 9.12 UK - Market size and forecast 2022-2027 Exhibit 107: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibit 108: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibit 109: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 110: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.13 Market opportunity by geography Exhibit 111: Market opportunity by geography ($ million) Exhibit 112: Data Tables on Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 113: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 114: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 115: Overview on factors of disruption 11.4 Industry risks Exhibit 116: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 117: Vendors covered 12.2 Market positioning of vendors Exhibit 118: Matrix on vendor position and classification 12.3 Asahi Kasei Corp. Exhibit 119: Asahi Kasei Corp. - Overview Exhibit 120: Asahi Kasei Corp. - Business segments Exhibit 121: Asahi Kasei Corp. - Key news Exhibit 122: Asahi Kasei Corp. - Key offerings Exhibit 123: Asahi Kasei Corp. - Segment focus 12.4 Avient Corp. Exhibit 124: Avient Corp. - Overview Exhibit 125: Avient Corp. - Business segments Exhibit 126: Avient Corp. - Key offerings Exhibit 127: Avient Corp. - Segment focus 12.5 BASF SE Exhibit 128: BASF SE - Overview Exhibit 129: BASF SE - Business segments Exhibit 130: BASF SE - Key news Exhibit 131: BASF SE - Key offerings Exhibit 132: BASF SE - Segment focus 12.6 Celanese Corp. Exhibit 133: Celanese Corp. - Overview Exhibit 134: Celanese Corp. - Business segments Exhibit 135: Celanese Corp. - Key offerings Exhibit 136: Celanese Corp. - Segment focus 12.7 Daicel Corp. Exhibit 137: Daicel Corp. - Overview Exhibit 138: Daicel Corp. - Business segments Exhibit 139: Daicel Corp. - Key offerings Exhibit 140: Daicel Corp. - Segment focus 12.8 DuPont de Nemours Inc. Exhibit 141: DuPont de Nemours Inc. - Overview Exhibit 142: DuPont de Nemours Inc. - Business segments Exhibit 143: DuPont de Nemours Inc. - Key news Exhibit 144: DuPont de Nemours Inc. - Key offerings Exhibit 145: DuPont de Nemours Inc. - Segment focus 12.9 Ensinger GmbH Exhibit 146: Ensinger GmbH - Overview Exhibit 147: Ensinger GmbH - Product / Service Exhibit 148: Ensinger GmbH - Key offerings 12.10 Inventro Polymers Exhibit 149: Inventro Polymers - Overview Exhibit 150: Inventro Polymers - Product / Service Exhibit 151: Inventro Polymers - Key offerings 12.11 Kolon Plastics Inc. Exhibit 152: Kolon Plastics Inc. - Overview Exhibit 153: Kolon Plastics Inc. - Product / Service Exhibit 154: Kolon Plastics Inc. - Key offerings 12.12 Korea Engineering Plastics Co. Ltd. Exhibit 155: Korea Engineering Plastics Co. Ltd. - Overview Exhibit 156: Korea Engineering Plastics Co. Ltd. - Product / Service Exhibit 157: Korea Engineering Plastics Co. Ltd. - Key offerings 12.13 LG Chem Ltd. Exhibit 158: LG Chem Ltd. - Overview Exhibit 159: LG Chem Ltd. - Business segments Exhibit 160: LG Chem Ltd. - Key news Exhibit 161: LG Chem Ltd. - Key offerings Exhibit 162: LG Chem Ltd. - Segment focus 12.14 Mitsubishi Chemical Corp. Exhibit 163: Mitsubishi Chemical Corp. - Overview Exhibit 164: Mitsubishi Chemical Corp. - Business segments Exhibit 165: Mitsubishi Chemical Corp. - Key news Exhibit 166: Mitsubishi Chemical Corp. - Key offerings Exhibit 167: Mitsubishi Chemical Corp. - Segment focus 12.15 Saudi Basic Industries Corp. Exhibit 168: Saudi Basic Industries Corp. - Overview Exhibit 169: Saudi Basic Industries Corp. - Business segments Exhibit 170: Saudi Basic Industries Corp. - Key offerings Exhibit 171: Saudi Basic Industries Corp. - Segment focus 12.16 Westlake Plastics Exhibit 172: Westlake Plastics - Overview Exhibit 173: Westlake Plastics - Product / Service Exhibit 174: Westlake Plastics - Key offerings 12.17 Yuntianhua Group Co. Ltd. Exhibit 175: Yuntianhua Group Co. Ltd. - Overview Exhibit 176: Yuntianhua Group Co. Ltd. - Product / Service Exhibit 177: Yuntianhua Group Co. Ltd. - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 178: Inclusions checklist Exhibit 179: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 180: Currency conversion rates for US$ 13.4 Research methodology Exhibit 181: Research methodology Exhibit 182: Validation techniques employed for market sizing Exhibit 183: Information sources 13.5 List of abbreviations Exhibit 184: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

2023-05-09

·蒲公英Ouryao

160个品种和80个技术方法→国家药品标准提高工作通知来了

转自：药典委员会整理：wangxinglai20042023年05月09日，国家药典委员会发布了《关于做好2023年度国家药品标准提高工作的通知》，本次标准提高共计涉及160个品种和80个技术方法。2023年国家标准提高重点内容1、涉及品种：苍术、沉香、川楝子、大黄、淡豆豉、甘草、炙甘草、枸杞子、广藿香、何首乌、制何首乌、花椒、降香、沉香化滞丸、半夏露颗粒、宽胸利膈丸、润肠丸(浓缩丸/水蜜丸) 、五加参归芪精、宝宝乐、小儿感冒颗粒（茶，口服液）、小儿吐泻宁散、阿拉坦五味丸、澳泰乐颗粒、苁黄补肾丸、二天油、风湿药丸、复方矮地茶片、复方板蓝根颗粒、复方荆芥熏洗剂、脑栓通胶囊、清热祛湿颗粒、麝香牛黄丸、麝香通心滴丸盐酸托莫西汀、盐酸托莫西汀胶囊、盐酸托莫西汀口服溶液、磷酸铝凝胶、壬苯醇醚、注射用米卡芬净钠、头孢呋辛酯、头孢呋辛酯胶囊、磺胺嘧啶锌、磺胺嘧啶锌软膏、聚乙二醇化重组人粒细胞刺激因子注射液、聚乙二醇化人生长激素注射液、利妥昔单抗、英夫利西单抗、曲妥珠单抗、贝伐珠单抗、四价流感病毒裂解疫苗、I型III型脊髓灰质炎减毒活疫苗糖丸(人二倍体细胞) 、双价人乳头瘤病毒疫苗(毕赤酵母) 、冻干b型流感嗜血杆菌结合疫苗、13价肺炎球菌多糖结合疫苗、环拉酸钠、混合脂肪酸甘油酯（硬脂）、聚甲丙烯酸铵酯Ⅰ、聚甲丙烯酸铵酯Ⅱ、磷酸钙、石蜡、甜菊糖苷、无水亚硫酸钠； 2、涉及通用技术方法：动物药来源及拉丁名规范研究、显微鉴别方法学研究、药材和饮片填平补齐（完善标准）、植物药来源及拉丁名规范研究、性状显微鉴别项梳理研究Ⅲ、高风险重金属及有害元素残留药材及饮片风险评估、中成药标准中乌头和马钱子类限量检查和含量测定方法及指导原则研究、细胞治疗产品总论、单克隆抗体Fc段介导效应功能评价方法研究、注射用人白介素-11生物学活性测定质量标准研究、免疫电泳法电泳缓冲液替代研究、采用体外效价测定方法替代动物体内试验用于生物制品质量控制的相关技术指导原则、间充质干细胞生物学效力检测方法的研究与开发、抗体类产品中蛋白A残留测定法、基于Nb2-11细胞增殖的人生长激素生物学活性测定方法研究、无细胞百白破联合疫苗有效组分鉴别试验(多重竞争抑制法) 、天平与称量指导原则的增订、水活度测定法的增订、0441核磁共振波谱法的修订、0431质谱法的修订、0982粒度和粒度分布测定法激光光散射法的修订、原子量表的规范化研究、蛋白质组学分析方法及应用指导原则的研究、0931溶出度与释放度测定法浸没池法的建立、溶液电导率测定法的增订、光学显微镜法的增订、基于红外光谱法和拉曼光谱法的0981结晶性检查法的修订与应用研究、近红外光谱法的修订、1001聚合酶链式反应法的修订、9014微粒制剂指导原则修订、0105眼用制剂通则修订、0127洗剂通则修订、微生物MALDI-TOFMS菌种鉴定技术指导原则的研究、药品微生物快速检测技术指导原则的研究、药用辅料粉体流动性测定—剪切池法、药用辅料熔融黏度测定法、充填剂转矩流变性的表征及评价方法研究、复杂药用辅料关键质量属性指标的定量核磁控制研究、中国药典药用辅料标准残留溶剂控制相关标准的研究、中国药典药用辅料标准元素杂质控制相关标准的研究、药品包装系统密封性研究指导原则、药品包装系统密封性检查法、药包材检验规则指导原则、预灌封注射器相关通则、预灌封注射器通则配套通用检测方法、笔式注射器相关通则、《药包材生物学评价与试验选择指导原则》配套检查法、药品包装用橡胶密封件相关通则、药品包装用橡胶密封件配套通用检测方法、《药包材中金属元素金属离子测定法》起草、《药包材不溶性微粒测定法》起草、《药包材溶出物测定法》起草、药品包装用玻璃容器相关通则。3、通知原文各有关单位：按照国家药典委员会《药品标准制修订研究课题管理办法》（以下简称“管理办法”），经公开征集课题建议及承担单位、组织专业委员会及专家组审议、网上公示、药典委审核等程序，确定了2023年度国家药品标准提高任务，具体如下：为确保2023年度国家药品标准提高工作顺利开展，现将有关事项通知如下：一、严格执行管理办法，按照《国家药品标准制修订研究课题合同书》及其附件确定的工作任务、研究目标、考核指标、经费预算，确保工作进度，确保工作质量。二、起草单位、复核单位和牵头单位按照经费性质分别填报相应的电子版和纸质版合同书（详见附件3、4），其中，由国家药典委员会拨付课题经费的承担单位填写A类合同（附件3），由承担单位自行解决课题经费的填写B类合同（附件4）。请自本通知发布之日起十五日内，将电子版合同书按照类别发送至相应处室联系人邮箱。待审核通过并告知你单位后，再请将加盖本单位公章的纸质版合同书按照类别寄送至相应处室。我委签署合同后，将分送至相关单位。各处室联系人及方式如下：中药处：赵宇新（010－67079523；zy@chp.org.cn）化学药品处：王志军（010－67079559；hybztg@chp.org.cn）生物制品处：陈慧毅（010－67079527；chenhuiyi@chp.org.cn）通则辅料包材处：朱冉（010－67079581；chp4@chp.org.cn）通讯地址：北京市东城区法华南里11号楼（邮编：100061）点击阅读原文下载附件

疫苗细胞疗法

2013-07-24

·BioSpace

Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora&#0174 Non-hormonal Contraceptive Gel

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today! DURHAM, N.C, July 24, 2013 /PRNewswire-iReach/ -- Health Decisions, Inc., the leading clinical research organization focusing on efficiency in execution of clinical development, today announced early completion of enrollment for a 3,384-subject phase III registration study of Evofem LLC's Amphora® nonhormonal contraceptive gel. (Photo: ) The global trial compares Amphora to Conceptrol®, the brand name of nonoxynol-9, and the only spermicidal gel currently approved by the FDA. "We are pleased that our focus on efficiency enabled us to enroll this important study well ahead of schedule," said Health Decisions CEO Michael Rosenberg, MD, MPH. "Our ability to use technology to enroll studies faster and to better retain subjects enables us to generate information more quickly than industry norms. This study is a good example and will provide Evofem with an earlier market entry than would otherwise have been possible." Dr. Rosenberg attributed successful enrollment of the Amphora study to the power of Agile Clinical Development, Health Decisions' award-winning, technology-leveraged approach to running clinical trials based on immediate, actionable information from the field. "Our approach and supporting technologies enable us to enroll over 80% of our studies on time or early when the rest of the industry is enrolling about 80% late," Rosenberg said. "In the Amphora study, our integrated adaptive enrollment techniques enabled us to enroll almost 3,400 subjects three to four times faster than previous trials of similar products that enrolled less than half as many subjects." Health Decisions enrolled the Amphora study at a rate of 125 subjects per month compared with 38 subjects per month and 30 subjects per month for previous large studies of similar products. One such study with a target enrollment of 1,800 subjects was terminated without meeting its enrollment goals. "We are very pleased with the progress on the development of Amphora," said Tommy G. Thompson, former US Health and Human Services Secretary, and Chairman of the Evofem Board of Directors. "Evofem is committed to providing women around the world with greater contraceptive choice and we expect Amphora to fill a critical gap in the market as an inexpensive, easy-to-use product that is woman-controlled and used only when necessary, on-demand." Dr. Rosenberg also noted, "Our integrated adaptive monitoring approach works on the same real-time principles as adaptive enrollment and also provided striking benefits in the Amphora trial, simultaneously reducing monitoring costs and increasing data quality." Health Decisions won the prestigious 2013 CIO 100 Award for its innovative adaptive monitoring technology. About Health Decisions Health Decisions is the leading clinical research organization (CRO) in Agile Clinical Development, providing proactive trial management based on real-time actionable information, enabling decisions that accelerate clinical studies and programs. For the drug and device industries, Agile Clinical Development provides a way to get new products to market faster and at lower cost. For the public, it means earlier access to improved treatments and diagnostics at more affordable prices. Founded in 1989, Health Decisions has conducted a range of successful clinical trials involving tens of thousands of patients, consistently reducing sponsors' financial risk and time to market. Privately held, Health Decisions is headquartered in Durham, NC and operates on all five continents. About Evofem Evofem LLC is a privately held biotechnology company that brings advanced prescription and consumer products to global markets. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, Evofem discovers, develops and commercializes prescription and over-the-counter products, in the areas of dermatology, pain management, feminine care, contraception, and the prevention of sexually transmitted infections. In February 2013, Evofem entered into a strategic alliance with WomanCare Global, a nonprofit organization whose mission is to provide access to quality, affordable, women's healthcare products through a sustainable supply chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, WomanCare Global provides sales, marketing and global distribution support to Evofem's products. News distributed by PR Newswire iReach: SOURCE Health Decisions Help employers find you! Check out all the jobs and post your resume.

100 项与壬苯醇醚-9 相关的药物交易

登录后查看更多信息